GB0013927D0 - Combination therapy - Google Patents

Combination therapy

Info

Publication number
GB0013927D0
GB0013927D0 GB0013927A GB0013927A GB0013927D0 GB 0013927 D0 GB0013927 D0 GB 0013927D0 GB 0013927 A GB0013927 A GB 0013927A GB 0013927 A GB0013927 A GB 0013927A GB 0013927 D0 GB0013927 D0 GB 0013927D0
Authority
GB
United Kingdom
Prior art keywords
combination therapy
therapy
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB0013927A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Angiogene Pharmaceuticals Ltd
Original Assignee
Angiogene Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiogene Pharmaceuticals Ltd filed Critical Angiogene Pharmaceuticals Ltd
Priority to GB0013927A priority Critical patent/GB0013927D0/en
Publication of GB0013927D0 publication Critical patent/GB0013927D0/en
Priority to EEP200200565A priority patent/EE200200565A/en
Priority to JP2001572111A priority patent/JP2003528920A/en
Priority to PT01915490T priority patent/PT1272199E/en
Priority to MXPA02009604A priority patent/MXPA02009604A/en
Priority to SI200130311T priority patent/SI1272199T1/xx
Priority to RU2002129097/15A priority patent/RU2268729C2/en
Priority to AU4258101A priority patent/AU4258101A/en
Priority to US10/240,213 priority patent/US6906048B2/en
Priority to AU2001242581A priority patent/AU2001242581B2/en
Priority to AT01915490T priority patent/ATE287267T1/en
Priority to NZ521025A priority patent/NZ521025A/en
Priority to CZ20023228A priority patent/CZ20023228A3/en
Priority to EP01915490A priority patent/EP1272199B1/en
Priority to SK1391-2002A priority patent/SK13912002A3/en
Priority to BR0109672-9A priority patent/BR0109672A/en
Priority to PCT/GB2001/001317 priority patent/WO2001074368A1/en
Priority to CA002402539A priority patent/CA2402539A1/en
Priority to KR1020027013061A priority patent/KR20020087456A/en
Priority to IL15162801A priority patent/IL151628A0/en
Priority to DK01915490T priority patent/DK1272199T3/en
Priority to PL01366379A priority patent/PL366379A1/en
Priority to ES01915490T priority patent/ES2236199T3/en
Priority to DE60108489T priority patent/DE60108489T2/en
Priority to HU0300290A priority patent/HUP0300290A3/en
Priority to CN01807444A priority patent/CN1430515A/en
Priority to IS6558A priority patent/IS6558A/en
Priority to NO20024646A priority patent/NO20024646L/en
Priority to US10/994,639 priority patent/US20050107346A1/en
Ceased legal-status Critical Current

Links

GB0013927A 2000-03-21 2000-06-08 Combination therapy Ceased GB0013927D0 (en)

Priority Applications (29)

Application Number Priority Date Filing Date Title
GB0013927A GB0013927D0 (en) 2000-06-08 2000-06-08 Combination therapy
EEP200200565A EE200200565A (en) 2000-03-31 2001-02-27 Combination therapy with vascular adverse effects
CN01807444A CN1430515A (en) 2000-03-31 2001-03-27 Divided dose therapies with vascular damaging activity
SK1391-2002A SK13912002A3 (en) 2000-03-31 2001-03-27 Combination therapies with vascular damaging activity
BR0109672-9A BR0109672A (en) 2000-03-31 2001-03-27 Use of zd6126 or a pharmaceutically acceptable salt thereof and one of: a plantin antitumor agent and a taxane, pharmaceutical composition, combination product, kit, and method for producing a vascularly damaging effect on a warm-blooded animal
MXPA02009604A MXPA02009604A (en) 2000-03-31 2001-03-27 Combination therapies with vascular damaging activity.
SI200130311T SI1272199T1 (en) 2000-03-31 2001-03-27
RU2002129097/15A RU2268729C2 (en) 2000-03-31 2001-03-27 Combined therapies using of angiogenesis damaging activity
AU4258101A AU4258101A (en) 2000-03-31 2001-03-27 Combination therapies with vascular damaging activity
US10/240,213 US6906048B2 (en) 2000-03-31 2001-03-27 N-acetylcolchinol-O-phosphate combination therapies with vascular damaging activity
AU2001242581A AU2001242581B2 (en) 2000-03-31 2001-03-27 Combination therapies with vascular damaging activity
AT01915490T ATE287267T1 (en) 2000-03-31 2001-03-27 COMBINATION THERAPIES WITH VASCULAR DAMAGE ACTIVITY
NZ521025A NZ521025A (en) 2000-03-31 2001-03-27 Combination and split dose therapies of ZD6126 and either a platinum anti-tumor agent, i.e. cisplatin, carboplatin oxaliplatin or ZD0473, a taxane, i.e. paclitaxel or docetaxel, or ionising radiation with vascular damaging activity
CZ20023228A CZ20023228A3 (en) 2000-03-31 2001-03-27 Pharmaceutical preparations used for inducing blood vessel-damaging effect
EP01915490A EP1272199B1 (en) 2000-03-31 2001-03-27 Combination therapies with vascular damaging activity
JP2001572111A JP2003528920A (en) 2000-03-31 2001-03-27 Combination therapy with vascular damaging activity
PT01915490T PT1272199E (en) 2000-03-31 2001-03-27 COMBINATION THERAPIES WITH LESAO VASCULAR ACTIVITY
PCT/GB2001/001317 WO2001074368A1 (en) 2000-03-31 2001-03-27 Combination therapies with vascular damaging activity
CA002402539A CA2402539A1 (en) 2000-03-31 2001-03-27 Combination therapies with vascular damaging activity
KR1020027013061A KR20020087456A (en) 2000-03-31 2001-03-27 Combination therapies with vascular damaging activity
IL15162801A IL151628A0 (en) 2000-03-31 2001-03-27 Combination therapies with vascular damaging activity
DK01915490T DK1272199T3 (en) 2000-03-31 2001-03-27 Combination therapies with vascular damage activity
PL01366379A PL366379A1 (en) 2000-03-31 2001-03-27 Combination therapies with vascular damaging activity
ES01915490T ES2236199T3 (en) 2000-03-31 2001-03-27 COMBINATION THERAPIES WITH VASCULAR DETERIORATION ACTIVITY.
DE60108489T DE60108489T2 (en) 2000-03-31 2001-03-27 COMBINATION THERAPIES WITH VULNERABLE ACTIVITY
HU0300290A HUP0300290A3 (en) 2000-03-31 2001-03-27 Combination therapies with vascular damaging activity
IS6558A IS6558A (en) 2000-03-31 2002-09-20 Mixed disease treatment with vasoconstrictor
NO20024646A NO20024646L (en) 2000-03-31 2002-09-27 Combination therapies with vasculature-damaging activity
US10/994,639 US20050107346A1 (en) 2000-03-21 2004-11-23 N-acetylcolchinol-o-phosphate combination therapies with vascular damaging activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0013927A GB0013927D0 (en) 2000-06-08 2000-06-08 Combination therapy

Publications (1)

Publication Number Publication Date
GB0013927D0 true GB0013927D0 (en) 2000-08-02

Family

ID=9893205

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0013927A Ceased GB0013927D0 (en) 2000-03-21 2000-06-08 Combination therapy

Country Status (1)

Country Link
GB (1) GB0013927D0 (en)

Similar Documents

Publication Publication Date Title
GB0028429D0 (en) Therapy
EP1296698A4 (en) Therapeutic agents - ii
GB0009606D0 (en) Therapeutic combinations
GB0012671D0 (en) Therapeutic agents
GB0003397D0 (en) Therapeutic agents
GB0004003D0 (en) Therapeutic agents
GB0018473D0 (en) Therapeutic agents
GB0017256D0 (en) Therapeutic agents
GB0126879D0 (en) Combination therapy
GB0027561D0 (en) Therapeutic agents
GB0005789D0 (en) Therapeutic agents
GB0007907D0 (en) Therapeutic agents
GB0012214D0 (en) Therapeutic agents
GB0008696D0 (en) Therapeutic agents
GB0023610D0 (en) Therapeutic agents
GB0000564D0 (en) Therapeutic agents
GB0020721D0 (en) Therapeutic agents
GB0017518D0 (en) Therapeutic agents
GB0108485D0 (en) Combination therapy
GB0007376D0 (en) Therapeutic agents
GB0017543D0 (en) Therapeutic agents
HU0200253D0 (en) Combination therapy
GB0022988D0 (en) Therapeutic agents
GB0007740D0 (en) Combination therapy
GB0014133D0 (en) Combination therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)